arthritis otezla vs rinvoq with savings for patients

Otezla is prescribed to adults who have active psoriatic arthritis.

Otezla and Rinvoq are from different drug classes. Otezla is a phosphodiesterase 4 (PDE4) inhibitor and Rinvoq is a Janus kinase (JAK) inhibitor.

Rinvoq and Otezla are known to cause upper respiratory tract infections, nausea, and cough.

Fever is one of the different side effects of Rinvoq from Otezla.

Diarrhea, headache, nausea, upper respiratory tract infection, vomiting, runny or stuffy nose, abdominal pain, fatigue, indigestion, heartburn, decreased appetite, insomnia, back pain, frequent bowel movements, depression, bronchitis, toot abscess, sinus headache, weight loss, gastroesophageal reflux disease (GERD), migraine, cough, and rash are the most common side effects of Otezla.
 

On the other hand, RINVOQ, on the other hand, is a JAK inhibitor that acts within your cells to disrupt certain signals considered to be the source of inflammation.

RINVOQ, a once-daily medication, has been demonstrated in clinical tests to help manage symptoms in 6 illnesses.

Adults with moderate to severe rheumatoid arthritis (RA) who have tried one or more tumour necrosis factor (TNF) blocker medications but found that they did not work or could not be tolerated might take RINVOQ, a prescription medication.
 

Adults with active psoriatic arthritis (PsA) who have tried one or more TNF blockers but found that they either did not function as well as expected or were intolerable.